据估算，预计市场产品数量将减少30%-40%，但临床常用、疗效确切的品种将通过补充研究得以保 留。 第二问：家中常备药是否安全？ "此前购买的板蓝根、连花清瘟等常用中成药还能用吗？"针对公众关心的这个问题，刘安表 示："已上市流通的药品不受直接影响，消费者可正常使用。" 中药说明书上那些模棱两可的"尚不明确"，即将成为历史。 距离2026年7月1日仅剩不到半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进 入最后窗口期。这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满3年起，说明书 【禁忌】【不良反应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请将依法不予通 过。 这意味着，国内现存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的批文将面 临淘汰。文件出台的背景是什么，将对中医药行业产生什么影响？1月28日，科技日报记者就上述问题 采访了中国工程院院士张伯礼以及相关业内专家。 第一问：中成药为何存在安全信息缺失问题？ 中国工程院院士张伯礼介绍，从近5年国家药品不良反应/事件报告看，中药占12%，化药占81%， 中药相对安全。该规定的出台，核心目的 ...

科技日报记者 付丽丽 第二问：家中常备药是否安全？ "此前购买的板蓝根、连花清瘟等常用中成药还能用吗？"针对公众关心的这个问题，刘安表示："已上 市流通的药品不受直接影响，消费者可正常使用。" 中药说明书上那些模棱两可的"尚不明确"，即将成为历史。 距离2026年7月1日仅剩不到半年时间，国家药监局《中药注册管理专门规定》第七十五条的落地进入最 后窗口期。这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满3年起，说明书【禁 忌】【不良反应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请将依法不予通过。 这意味着，国内现存约5.7万个中成药有效批准文号中，超70%存在安全信息标注问题的批文将面临淘 汰。文件出台的背景是什么，将对中医药行业产生什么影响？1月28日，科技日报记者就上述问题采访 了中国工程院院士张伯礼以及相关业内专家。 第一问：中成药为何存在安全信息缺失问题？ 中国工程院院士张伯礼介绍，从近5年国家药品不良反应/事件报告看，中药占12%，化药占81%，中药 相对安全。该规定的出台，核心目的是补齐中药说明书安全信息短板，推动中药产业高质量发展。 据了解，我国中成药多数获 ...

格隆汇1月28日｜河南印发河南省提升中药质量促进中医药产业高质量发展若干政策措施的通知。优化 中药产业布局。支持中原医学科学城、省中医药科学院建设，打造中医药健康产业高地。培育3—5个年 营业收入超过30亿元的中药企业，建设具有全国影响力的中药产业集群。培育发展一批中药领域专精特 新中小企业。以"中药+"促进产业延链发展，丰富保健食品、食药物质等产品高质量供给。支持南阳艾 草、焦作怀药等单药产业全链条集聚发展。争取开展国家中医药事业产业协同创新试点。 ...

Core Insights - The conference focused on "Brand Leadership, Technological Empowerment, and Promoting High-Quality Development" in the traditional Chinese medicine (TCM) industry, gathering over 700 participants from various sectors to discuss innovation and development strategies [1][2] Group 1: Conference Highlights - The China Traditional Chinese Medicine Association launched a quality technology platform for the entire TCM industry chain, aiming to enhance quality control and industry resilience [2] - The conference featured keynote speeches from experts discussing innovation in TCM and regulatory practices, emphasizing the integration of traditional and modern medicine [2][3] - Several reports were released, including the "China TCM Decoction Piece Industry Development Report (2024-2025)" and the "China Ganoderma Industry Development Report," showcasing advancements and research in the field [3] Group 2: Achievements and Future Directions - The China Traditional Chinese Medicine Association celebrated its 25th anniversary, highlighting its commitment to serving the industry and promoting sustainable use of TCM resources [4] - The association aims to strengthen its professional, platform-based, and digital service capabilities to support the modernization and internationalization of the TCM industry [4] - Future initiatives will focus on enhancing the quality and efficiency of the entire TCM industry chain, aligning with national health strategies and the demand for TCM [4]

Core Viewpoint - Yunnan Baiyao reported record high performance for the first half of 2025, with a net profit growth of double digits, and announced a special dividend plan [1] Financial Performance - Revenue for the first half of 2025 reached 21.257 billion yuan, a year-on-year increase of 3.92% [1] - Net profit attributable to shareholders was 3.633 billion yuan, up 13.93% year-on-year, marking a historical high for the period [1] - Non-recurring net profit was 3.461 billion yuan, a 10.40% increase year-on-year [1] - Basic earnings per share were 2.04 yuan, reflecting a 13.97% growth [1] - Operating cash flow net amount was 3.961 billion yuan, up 21.45% year-on-year [1] Business Strategy and Development - The company has implemented a new model for party building, enhancing cohesion and competitiveness, which supports high-quality development [2] - Yunnan Baiyao is focusing on optimizing resource allocation and improving management capabilities as part of its strategic planning for 2024-2028 [2] Industrial and Product Performance - The industrial segment's revenue accounted for 40.01% of total revenue, with an increase of 2.6 percentage points year-on-year, and an industrial revenue growth rate of 11.13% [3] - The pharmaceutical sector achieved a revenue of 4.751 billion yuan, growing by 10.8% year-on-year, with significant sales increases in various product lines [3] - The health products segment generated 3.442 billion yuan in revenue, a 9.46% increase, maintaining a leading market share in toothpaste [4] - The commercial segment reported a revenue of 12.164 billion yuan, with a net profit of 351 million yuan, reflecting a 17.75% increase [5] Innovation and R&D - Yunnan Baiyao is advancing its R&D efforts with a focus on both traditional Chinese medicine and innovative drugs, with several projects in various stages of clinical trials [8] - The company has adopted a precise R&D and transformation model for its seed industry, achieving significant growth in the number of shipments despite market price pressures [7] Digital Transformation - The company is enhancing its digital transformation through AI and data technologies, achieving over 1 billion yuan in online business transactions [10] - A fully automated settlement process has been established, significantly reducing paper usage and improving operational efficiency [10] Future Outlook - Yunnan Baiyao aims to leverage strategic mergers and acquisitions to achieve sustainable growth and enhance investor returns, aligning with national policies to improve the quality of traditional Chinese medicine [11]

Core Viewpoint - The company achieved significant growth in Q1 2025, with revenue of 289 million yuan, a year-on-year increase of 13.52%, and a net profit attributable to shareholders of 24.21 million yuan, up 9.18%, marking the end of three consecutive quarters of decline [1] Financial Performance - The company reported a net profit of 26.92 million yuan after deducting non-recurring items, reflecting a year-on-year growth of 26.88% [1] - The revenue from the company's main products, including Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, contributed to the stable growth in Q1 [1] Product Development and Market Strategy - The company focuses on its core business and actively develops OTC and untapped markets, which has laid a solid foundation for revenue growth [1] - The core product, Xuanfei Zhiso Heji, has shown strong sales growth, with revenue reaching 840 million yuan in 2024, a 29.76% increase from the previous year [2] - The company is upgrading its production capacity for Xuanfei Zhiso Heji, with a new production line set to be operational in May 2024, enhancing market supply capabilities [2] Innovation and R&D - The company has acquired 70% of the shares in an innovation research institute, which will accelerate the transformation of research results and improve product quality and competitiveness [3] - The company is also developing new products, including a blood dialysis concentrate and a plant-based beverage, while continuing to enhance its main products [3] Future Outlook - The company aims to maintain its focus on core operations and market expansion, with plans to implement various annual work tasks to improve operational efficiency [4]